The United States Food and Drug Administration (FDA) has approved United States-based PTC Therapeutics Inc's. (NASDAQ: PTCT) Evrysdi (risdiplam), the first at-home, orally administered treatment for spinal muscular atrophy in adults and children two months and older, it was reported on Friday.
The product indicated clinical improvement in motor function and received developmental milestones across two trials in patients aged two months and above and across all levels of disease severity, including types one, two, and three spinal muscular atrophy.
Evrysdi was studied in a clinical trial program in spinal muscular atrophy with over 450 patients and subjects. It will be offered in the United States within two weeks for direct delivery to patients' homes via Accredo Health Group Inc, an Express Scripts specialty pharmacy.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval